乳腺癌分子分型指导乳房重建规划
该研究回顾1999年11月至2012年12月间1931例乳腺癌乳房切除并重建病例,按乳腺癌分子分型分组,分析分型与无复发生存及乳房切除术后放疗需求的关系。结果显示不同分型放疗比例和生存差异显著,分型可能改善部分延迟或即刻重建的手术规划。
要点
- HER2富集型乳房切除术后放疗比例最高(48.3%),luminal A型最低(29.5%)。
- Luminal A型无复发生存最佳,三阴性型无复发生存较HER2富集型更差。
- 分型可能改善33.1%不需放疗的延迟重建和37%需放疗的即刻重建的规划。
核心结论
- 本研究首次评估乳腺癌分子分型用于乳房重建决策中的风险分层。
研究设计与样本
- 回顾性分析前瞻性收集的1931例乳腺癌乳房切除重建病例,手术时间1999年11月至2012年12月。
主要发现
- 重建乳房中luminal A型753例(39%),luminal B型538例(27.9%),luminal HER2型224例(11.6%),HER2富集型143例(7.4%),三阴性型267例(13.8%)。
- 乳房切除术后放疗:HER2富集型69例(48.3%),luminal HER2型94例(42%),luminal B型200例(37.2%),三阴性型99例(37.1%),luminal A型222例(29.5%)(p < 0.0001)。
- Luminal A型无复发生存优于HER2富集型,三阴性型无复发生存差于HER2富集型。
- Luminal B型和luminal HER2型无复发生存与HER2富集型相似,luminal A型无复发生存最佳。
- 分型可能改善33.1%不需放疗的延迟重建和37%需放疗的即刻重建的手术规划。
临床怎么用
- 可利用乳腺癌分子分型预测乳房切除术后放疗需求和复发风险,辅助选择重建时机与术式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular profiling using breast cancer subtype has an increasing role in the multidisciplinary care of the breast cancer patient. The authors sought to determine the role of breast cancer subtyping in breast reconstruction and specifically whether breast cancer subtyping can determine the need for postmastectomy radiation therapy and predict recurrence-free survival to plan for the timing and technique of breast reconstruction. METHODS: The authors reviewed prospectively collected data from 1931 reconstructed breasts in breast cancer patients who underwent mastectomy between November of 1999 and December of 2012. Reconstructed breasts were grouped by breast cancer subtype and examined for covariates predictive of recurrence-free survival and need for postmastectomy radiation therapy. RESULTS: Of the reconstructed breasts, 753 (39 percent) were luminal A, 538 (27.9 percent) were luminal B, 224 (11.6 percent) were luminal HER2, 143 (7.4 percent) were HER2-enriched, and 267 (13.8 percent) were triple-negative breast cancer. Postmastectomy radiation therapy was delivered in 69 HER2-enriched patients (48.3 percent), 94 luminal HER2 patients (42 percent), 200 luminal B patients (37.2 percent), 99 triple-negative breast cancer patients (37.1 percent), and 222 luminal A patients (29.5 percent) (p < 0.0001). Luminal A cases had better recurrence-free survival than HER2-enriched cases, and triple-negative breast cancer cases had worse recurrence-free survival than HER2-enriched cases. Luminal B and luminal HER2 cases had recurrence-free survival similar to that for HER2-enriched cases. Luminal A subtype was associated with the best recurrence-free survival. Subtyping may have improved the breast surgery planning for 33.1 percent of delayed reconstructions that did not require postmastectomy radiation therapy and 37 percent of immediate reconstructions that did require postmastectomy radiation therapy. CONCLUSION: This study is the first publication in the literature to evaluate breast cancer subtype to stratify risk for decision making in breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.
引用
- Sandberg LJ, Clemens MW, Symmans WF, et al. Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg. 2017. PMID: 28234813. doi:10.1097/PRS.0000000000003050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。